SCHEMBL2763076

SCHEMBL2763076

Cc1ccc(-c2cc(Cl)nc(CN)n2)o1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.42
HPGD P15428 9/20 0.42
MAPT P10636 7/20 0.42
PKM P14618 7/20 0.42
KDM4E B2RXH2 7/20 0.42
GAA P10253 5/20 0.42
MEN1 O00255 5/20 0.42
KMT2A Q03164 5/20 0.42
GLA P06280 5/20 0.42
ALOX12 P18054 4/20 0.42
TSHR P16473 1/20 0.42
CASP1 P29466 3/20 0.41
CASP7 P55210 3/20 0.41
HSD17B10 Q99714 3/20 0.41
ALOX15 P16050 2/20 0.41
USP2 O75604 1/20 0.41
KAT8 Q9H7Z6 1/20 0.39
TDP1 Q9NUW8 3/20 0.39
HTT P42858 2/20 0.39
LMNA P02545 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2762992 0.82 ALDH1A1 (0.38) ALDH1A1HPGDMAPTPKMKDM4E
SCHEMBL930783 0.80 KDM4E (0.49) ALDH1A1HPGDMAPTPKMKDM4E
SCHEMBL2763257 0.79 ALDH1A1 (0.44) ALDH1A1HPGDMAPTPKMKDM4E
SCHEMBL929213 0.79 ALDH1A1 (0.44) ALDH1A1HPGDMAPTPKMKDM4E
SCHEMBL2763990 0.74 ADORA2A (0.46) ALDH1A1HPGDMAPTPKMKDM4E
SCHEMBL928465 0.74 ADORA2A (0.46) ALDH1A1HPGDMAPTPKMKDM4E
SCHEMBL7833405 0.70 LOXL2 (0.38) KDM4EKMT2A
SCHEMBL4969679 0.70 ADORA2A (0.44) ALDH1A1HPGDMAPTPKMKDM4E
SCHEMBL3096890 0.67 ADORA2A (0.46) ALDH1A1HPGDMAPTPKMKDM4E
SCHEMBL23828617 0.64 ADORA2A (0.40) ALDH1A1HPGDMAPTPKMKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1722798-B1 PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONISTS VERNALIS R&D LTD (GB) 2010-10-20 EP disclosed
US-20080182860-A1 Pyrimidine Compounds as Purine Receptor Antagonist VERNALIS (R&D) LTD. (GB) 2008-07-31 US disclosed
EP-1722798-A1 PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONIST VERNALIS (R&D) LTD (GB) 2006-11-22 EP disclosed
WO-2005079800-A1 PYRIMIDINE COMPOUNDS AS PURINE RECEPTOR ANTAGONIST VERNALIS (R & D) LTD. (GB) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080182860-A1 Pyrimidine Compounds as Purine Receptor Antagonist ADORA3, P2RY10, ADORA2A ALDH1A1 1455/4885HPGD 3498/4885MAPT 4220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.